Structural flexibility at a major conserved antibody target on Hepatitis C virus E2 antigen

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 45, 2016, Pages 12768-12773

  Kong, Leopold ^a,c   Lee, David E ^b   Kadam, Rameshwar U ^a   Liu, Tong ^b   Giang, Erick ^a   Nieusma, Travis ^a   Garces, Fernando ^a   Tzarum, Netanel ^a   Woods, Virgil L ^b   Ward, Andrew B ^a   Li, Sheng ^b   Wilson, Ian A ^a   Law, Mansun ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

CD81 binding site; Conformational flexibility; E2; Hepatitis C virus; Protein dynamics

Indexed keywords

CD81 ANTIGEN; HEPATITIS C VIRUS E2 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIBODY STRUCTURE; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DEUTERIUM HYDROGEN EXCHANGE; DIFFERENTIAL SCANNING CALORIMETRY; ELECTRON MICROSCOPY; ENTROPY; HEPATITIS C VIRUS; ISOTHERMAL TITRATION CALORIMETRY; MASS SPECTROMETRY; MELTING POINT; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR BINDING;

EID: 84994545682     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1609780113     Document Type: Article

References (72)

1. Messina JP, et al. (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77-87.
2. Thursz M, Fontanet A (2014) HCV transmission in industrialized countries and resourceconstrained areas. Nat Rev Gastroenterol Hepatol 11(1):28-35.
3. Feeney ER, Chung RT (2014) Antiviral treatment of hepatitis C. BMJ 348:g3308.
4. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH (2015) From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62(1, Suppl):S87-S99.
5. Zhang Z, et al. (2013) Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China. PLoS One 8(12):e82598.
6. Ly KN, et al. (2012) The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156(4):271-278.
7. Marco A, et al. (2013) Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 59(1):45-51.
8. Midgard H, et al. (2016) Hepatitis C reinfection after sustained virological response. J Hepatol 64(5):1020-1026.
9. Kong L, Jackson KN, Wilson IA, Law M (2015) Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol 11:148-157.
10. Walker CM, Grakoui A (2015) Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol 35:137-143.
11. Cox AL (2015) MEDICINE. Global control of hepatitis C virus. Science 349(6250):790-791.
12. Zona L, et al. (2014) CD81-receptor associations. impact for hepatitis C virus entry and antiviral therapies. Viruses 6(2):875-892.
13. Douam F, Lavillette D, Cosset FL (2015) The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci 129:63-107.
14. Kong L, et al. (2013) Hepatitis C virus E2 envelope glycoprotein core structure. Science 342(6162):1090-1094.
15. Owsianka AM, et al. (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80(17):8695-8704.
16. Drummer HE, Wilson KA, Poumbourios P (2002) Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J Virol 76(21):11143-11147.
17. Kong L, et al. (2012) Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J Virol 86(23):13085-13088.
18. Kong L, et al. (2012) Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci USA 109(24):9499-9504.
19. Potter JA, et al. (2012) Toward a hepatitis C virus vaccine: The structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol 86(23):12923-12932.
20. Pantua H, et al. (2013) Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 425(11):1899-1914.
21. Meola A, et al. (2015) Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. J Virol 89(4):2170-2181.
22. Li Y, et al. (2015) Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem 290(16):10117-10125.
23. Krey T, et al. (2013) Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog 9(5):e1003364.
24. Deng L, et al. (2013) Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. Proc Natl Acad Sci USA 110(18):7418-7422.
25. Law M, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14(1):25-27.
26. Giang E, et al. (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 109(16):6205-6210.
27. Ray R, et al. (2010) Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 202(6):862-866.
28. Meyer K, Banerjee A, Frey SE, Belshe RB, Ray R (2011) A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One 6(8):e23699.
29. Zhang P, et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 104(20):8449-8454.
30. Ruwona TB, Giang E, Nieusma T, Law M (2014) Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol 88(18):10459-10471.
31. Ball JK, Tarr AW, McKeating JA (2014) The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 105:100-111.
32. Wellnitz S, et al. (2002) Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 76(3):1181-1193.
33. Triyatni M, et al. (2002) Structural features of envelope proteins on hepatitis C viruslike particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 298(1):124-132.
34. McLellan JS, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480(7377):336-343.
35. Englander SW (2006) Hydrogen exchange and mass spectrometry: A historical perspective. J Am Soc Mass Spectrom 17(11):1481-1489.
36. Konermann L, Pan J, Liu YH (2011) Hydrogen exchange mass spectrometry for studying protein structure and dynamics. Chem Soc Rev 40(3):1224-1234.
37. Bale S, et al. (2011) Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl Trop Dis 5(11):e1395.
38. Kong L, et al. (2010) Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. J Virol 84(19):10311-10321.
39. Chen L, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326(5956):1123-1127.
40. Tokuriki N, Oldfield CJ, Uversky VN, Berezovsky IN, Tawfik DS (2009) Do viral proteins possess unique biophysical features? Trends Biochem Sci 34(2):53-59.
41. Khan AG, et al. (2014) Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509(7500):381-384.
42. Deng L, et al. (2014) Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization. Proc Natl Acad Sci USA 111(29):10690-10695.
43. Shi M, et al. (2007) A structural hypothesis for the transition between bent and extended conformations of the leukocyte-À2 integrins. J Biol Chem 282(41):30198-30206.
44. Smagghe BJ, Huang PS, Ban YE, Baker D, Springer TA (2010) Modulation of integrin activation by an entropic spring in the -À-knee. J Biol Chem 285(43):32954-32966.
45. Razvi A, Scholtz JM (2006) Lessons in stability from thermophilic proteins. Protein Sci 15(7):1569-1578.
46. Sanders RW, et al. (2013) A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not nonneutralizing antibodies. PLoS Pathog 9(9):e1003618.
47. Epand RM, Epand RF (2002) Thermal denaturation of influenza virus and its relationship to membrane fusion. Biochem J 365(Pt 3):841-848.
48. Brower ET, Schon A, Freire E (2010) Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Biochemistry 49(11):2359-2367.
49. Morar-Mitrica S, Nesta D, Crotts G (2013) Differential scanning calorimetry (DSC) for biopharmaceutical development: Old concepts, new applications. Biopharma Asia 2(4):44-55.
50. Deller MC, Kong L, Rupp B (2016) Protein stability: A crystallographer's perspective. Acta Crystallogr F Struct Biol Commun 72(Pt 2):72-95.
51. Myszka DG, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 97(16):9026-9031.
52. Sandomenico A, et al. (2016) Generation and characterization of monoclonal antibodies against a cyclic variant of hepatitis C virus E2 epitope 412-422. J Virol 90(7):3745-3759.
53. McLellan JS, et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592-598.
54. Guenaga J, et al. (2015) Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLoS Pathog 11(1):e1004570.
55. Kong L, et al. (2016) Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat Commun 7:12040.
56. Mendillo ML, et al. (2009) A conserved MutS homolog connector domain interface interacts with MutL homologs. Proc Natl Acad Sci USA 106(52):22223-22228.
57. Chen H, et al. (2010) Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc Natl Acad Sci USA 107(41):17621-17626.
58. Voss NR, Yoshioka CK, Radermacher M, Potter CS, Carragher B (2009) DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol 166(2):205-213.
59. Scheres SH, et al. (2005) Maximum-likelihood multi-reference refinement for electron microscopy images. J Mol Biol 348(1):139-149.
60. Frank J, et al. (1996) SPIDER and WEB: Processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol 116(1):190-199.
61. Ludtke SJ, Baldwin PR, Chiu W (1999) EMAN: Semiautomated software for high-resolution single-particle reconstructions. J Struct Biol 128(1):82-97.
62. Bowers KJ, et al. (2006) Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 2006 ACM/IEEE Conference on Supercomputing (SC06) (ACM Press, New York).
63. Erntell M, Myhre EB, Sjobring U, Bjorck L (1988) Streptococcal protein G has affinity for both Fab- and Fc-fragments of human IgG. Mol Immunol 25(2):121-126.
64. Hastie KM, et al. (2011) Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci USA 108(48):19365-19370.
65. Marsh JJ, et al. (2013) Structural insights into fibrinogen dynamics using amide hydrogen/deuterium exchange mass spectrometry. Biochemistry 52(32):5491-5502.
66. Suloway C, et al. (2005) Automated molecular microscopy: The new Leginon system. J Struct Biol 151(1):41-60.
67. Jorgensen WL, Maxwell DS, Tirado Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236.
68. Krautler V, van Gunsteren WF, Hunenberger PH (2001) A fast SHAKE: Algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J Comput Chem 22:501-508.
69. Martyna GJ, Tobias DJ, Klein ML (1994) Constant-pressure molecular-dynamics algorithms. J Chem Phys 101:4177-4189.
70. Hoover WG (1985) Canonical dynamics: Equilibrium phase-space distributions. Phys Rev A Gen Phys 31(3):1695-1697.
71. Darden TA, York DM, Pedersen LG (1993) Particle mesh Ewald: An N'Elog (N) method for Ewald sums in large systems. J Chem Phys 98:10089-10092.
72. Tuckerman M, Berne BJ, Martyna GJ (1992) Reversible multiple time scale moleculardynamics. J Chem Phys 97:1990-2001.